Biogen, Eisai win FDA nod for starter dose of subcutaneous Leqembi
Leqembi Iqlik can now be given at home throughout the entire course of treatment, setting it apart from Eli Lilly’s Kisunla, the only other anti-amyloid Alzheimer’s disease therapy on the market.
Read the full articleYou might also wanna read
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease
LEQEMBI IQLIK is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home dosing for initiation and maintenance (approved in t
Biogen (BIIB) Gains FDA Approval for Subcutaneous Alzheimer's Treatment Leqembi Iqlik
Related Stocks: BIIB
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026
New clinical and real-world data support a subcutaneous treatment pathway from initiation through maintenance treatment, offering dosing con
FDA approves at-home starter dose of Eisai-Biogen Alzheimer’s drug
(Refiles to add media packaging code, USA-HEALTH/ALZHEIMERS; no change to text or headline) July 13 (Reuters) - The U.S. FDA on Monday appro
FDA clears at-home start dose for Alzheimer's drug Leqembi
FDA clears at-home start dose for Alzheimer's drug Leqembi Phil.Taylor Tue, 14/07/2026 - 08:36
FDA Approves Leqembi: First Drug to Slow Alzheimer's Disease Progression
With the FDA giving the green light to Leqembi, there is renewed hope to millions, promising a potential game-changer in the fight against t
Comments
Sign in to join the conversation.
No comments yet. Be the first.